| Literature DB >> 26834096 |
David Groheux1, Alexandre Cochet2, Olivier Humbert2, Jean-Louis Alberini3, Elif Hindié4, David Mankoff5.
Abstract
Many studies have pointed out the role of (18)F-FDG PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer. (18)F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of (18)F-FDG PET/CT in restaging and how (18)F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.Entities:
Keywords: 18F-FDG PET/CT; breast cancer; prognosis; restaging; staging
Mesh:
Substances:
Year: 2016 PMID: 26834096 DOI: 10.2967/jnumed.115.157859
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057